Kissht previously raised $80 million in funding in 2022, at a valuation of about $344 million, from Vertex Growth and Brunei ...

OnEMI Technology, parent of Kissht, sees 55% growth in AUM to Rs 4,200 crore in FY25. The company expands into secured ...

This is today's edition of The Download, our weekday newsletter that provides a daily dose of what's going on in the world of ...

The universe’s expansion is accelerating, not decelerating. Our understanding of how the universe works may need an update.

Some of the categories provided by the two entities include: commercial permits, business permits, building permits, commercial certificates of occupancy, as well as abstracts of judgment, state and ...

Trump's upcoming tariffs has the potential to bring biopharma manufacturing to the US, which could impact companies with ...

The cloud giant AI wars are heating up with Google announcing its Gemini 2.5 model and Amazon countering with the launch of ...

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Listed 4iG group and space engineering company REMRED topped out a space technology manufacturing centre in Martonvásár, on ...

Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

Vertex Pharmaceuticals is flexing its innovation muscles beyond its cystic fibrosis stronghold, charging into new territories ...